<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A revival of interest in antithrombotic agents for the treatment of ischemic cerebrovascular disease has resulted in the widespread use of oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> for the prophylaxis and therapy of the ischemic variety of <z:hpo ids='HP_0001297'>stroke</z:hpo>, and has generated enthusiasm for the use of platelet-suppressant agents such as aspirin, <z:chebi fb="0" ids="4653">dipyridamole</z:chebi>, and <z:chebi fb="0" ids="9342">sulfinpyrazone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In delineating the several clinical types of focal ischemic disease and outlining the causes of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and infarction, the study group considers the problems of data interpretation in the face of inconsistent terminology </plain></SENT>
<SENT sid="2" pm="."><plain>The basic mechanisms of hemostasis and thrombogenesis are concisely detailed </plain></SENT>
<SENT sid="3" pm="."><plain>Finally, the study group critically reviews extensive earlier reports of clinical trials of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, platelet function suppressants, and thrombolytic agents, and reassesses according to present-day statistical standards the significance of the results </plain></SENT>
<SENT sid="4" pm="."><plain>The information contained in this report should familiarize the reader with sufficient data to permit him to utilize antithrombotic agents under a variety of circumstances and to appreciate the contraindications and potential dangers in their use </plain></SENT>
</text></document>